American Association for the Study of Liver Diseases (AASLD) 2025
November 7-11, 2025 | Washington, D.C.
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment
Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment
Dimension analysis of ENVISION study EQ-5D data to assess relationship between annualized attack rate and chronic symptoms in patients with acute hepatic porphyria
EXPLORE B post hoc analysis of chronic symptoms in patients with acute hepatic porphyria
